HEPATOLOGY 润色咨询

HEPATOLOGY

出版年份:1981 年文章数:5641 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:4.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2022-04-14 ms4000000877142304

    课题组的第二篇hepatology接收了。
    贡献一个timeline;
    11-nov-2021~21-dec-2021 reject with opportunity to resubmit
    8-apr-2022 修回,当天主编直接 accept
    总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。

    9

    展开9条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2023-06-20 1ddf3775m09(暂无匿称) 来自上海

    Submission Received状态一般会持续几天?

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2023-05-13 川云不息 来自浙江省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:临床转化;免疫;肝癌
    经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2020-05-14 xrkguoguo

    想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-02-05 半夜吹口哨

    请问作者签名确认必须完成才会送审吗?凱凱 2018-02-03 23:24:00 发表:
    2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
    總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

    凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
    總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2021-12-29 小动量

    方法的撰写顺序/逻辑顺序是什么?

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2022-12-10 ms6000001750417887 来自北京

    一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2022-10-30 wfkevinhan

    偏重的研究方向:侵袭转移机制;肝癌
    经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-07-30 liuxd6

    显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。<br>贡献一个timeline;<br>11-nov-2021~21-dec-2021 reject with opportunity to resubmit<br>8-apr-2022 修回,当天主编直接 accept<br>总体而言,数据量要大且充实,论据充分,临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么,修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=138, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:临床转化;免疫;肝癌<br>经验分享:中了一篇,杂志目前换了出版社,确实早该换了哈哈。编辑部审稿很认真,都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点,美肝比欧肝关注的肝病种类齐全,包括肝脏发育,罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=218, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097447, encodeId=c292209e4479d, content=偏重的研究方向:侵袭转移机制;肝癌<br>经验分享:投稿一天assigning/selecting reviewer,6天under review。不知道后面什么结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI8LFGcj43yiaxq5w72qblCubv1OHbeMOXPZ8qmia9tibRTaI1p9YmIm1yunNCLBkKVeFELATcgTiamIg/132, createdBy=80eb93372, createdName=wfkevinhan, createdTime=Sun Oct 30 11:41:48 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE,投稿一星期了,还是Selecting/Assigning Reviewers,困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=185, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=)]
    2019-10-10 qmac

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志

    2

    展开2条回复
共148条页码: 1/15页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分